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Abstract: Efficient small interfering RNA (siRNA) delivery into cells is the basis of target gene
specific silencing and, ultimately, gene therapy. However, current transfection reagents
are relatively inefficient and very few studies provide the sort of systematic
understanding based on structure-activity relationships that would provide rationales
for their improvement. This work establishes peptide dendrimers (administered with
cationic lipids) as siRNA transfection reagents and records structure-activity
relationships that highlight the importance of positive charge distributed in the two outer
layers and a hydrophobic core as key features for efficient performance. These
transfection reagents work as well as highly optimized commercial reagents, yet show
less toxicity and fewer off-target effects.  More generally, the degrees of freedom in the
synthetic procedure will allow the placing of decisive recognition features to enhance
and fine-tune transfection and cell specificity.
Response to Reviewers: Response to reviewers
=> Please note that changes are highlighted in red for the eyes of the reviewers (in
extra attached copies under the heading "additional material - authors" ) .
Reviewer 1
The authors might like to address the following minor points on preparing a definitive
version:
1.- The authors have chosen to limit the introductory paragraph to siRNA delivery
systems. Whereas I agree that the small size of siRNA as compared to pDNA or
mRNA often translate in differences on the performance of cationic carriers, in practice
most of them are polyvalent. I would rather suggest putting the focus on the molecular
and monodisperse character of PDs, analogous to other molecular nucleic acid vectors
reported in the literature and equally offering the possibility to conduct structure-activity
studies (which is rare in the field). It is worth it to explicitly mention this analogy in the
Introduction. Examples of those include calixarene, fullerene, pillarene, cyclodextrins
and other macrocyclic derivatives. The following references might be incorporated to
illustrate this point: Nat. Commun., 2013, 4, 1721-1727; Sci. Rep. 2014, 4, 4916;
Angew. Chem. Int. Ed. 2014, 53, 13126-13130 (note that the two later are examples of
siRNA delivery) ; Org. Biomol. Chem. 2015, 13, 1708-1723; Chem. Commun. 2016, 52,
10117-10120.
The introduction was changed accordingly and the references incorporated – p. 1, l. 4-
14/right “Furthermore, in many cases the molecular basis of the observed effects is
hard to delineate. Structure-activity relationships that would provide means to rationally
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
manipulate the observed effects are rare, emerging sometimes from polydisperse
systems [4c], but mainly from analysis of monodisperse reagents [2b, 11a, 12].”
2.- Page 1, column 1, line 37-38: the definition of the abbreviation siRNA should be
moved to line 30, first time it is mentioned.
Changed.
3.- Page 2, column 1, line 30: RL should be KL, I gather.
We could not locate this suggested correction. If the sentence “The best candidates,
G2,3-KL and G2,3-RL exhibited 70% and 65% gene knock down, respectively.” is
meant, this statement is correct (see Table 1 – here residual GAPDH activity is quoted
as the corresponding 30% and 35%.
4.- Page 3, column 2, line 2: strong uptake can be (remove , which). Line 44: that it is
(remove the).
Changed.
5. Note that the references format does not fit ChemBioChem's style and that some
journal names are not properly abbreviated (e.g. Angewandte Chemie)
Changed.
Reviewer 2
1.While the manuscript is generally well written, the discussion is a bit hard to follow.
The authors jump directly into the biological results (figure 2) first followed by the
biophysical evaluations in fig 4. As a result, the authors start with figure 2A and B, then
jump to fig 4 and then come back to figures 2E and F. A number of times, the results
and analysis and discussions are intertwined which make the narrative not as intuitive.
Why not discuss biophysical properties first, followed by cell uptake and finally the
biological results?
We have taken up the suggestion of the reviewer and changed the text to show first the
most important biological data and then the biophysical properties that give inside into
the possible mode of action of the dendrimers. Accordingly the data were rearranged,
leading to the splitting up of one figure.
2. What is DOTMA and DOPE - this should be clarified at first mention in manuscript.
Changed.
3. In general, the transfection agents do not outperform the gold standard
lipofectamine 2000 from the literature. The authors claim that their formulation is less
toxic based on minimal data showing greater knockdown of a control gene with L2000.
That bit of data is not very convincing and the formulation does not cause off-target
effects (it is toxic to cells) but the siRNA does. It just as likely that the enhanced activity
with L2000 (80% knockdown versus 70% knockdown with G2,3KL) is responsible for
these "off-target" effects.
We agree with the reviewer that the differences in cytotoxicity are small, but we still
show that they are significant: our conclusion is based on sextuplicate experiments
which were repeated 3-times, with the statistical analysis indicating significance.  It is
possible that the "off-target" effects are responsible for this, because the cell viability in
Fig. 2B was measured after transfection.
We have added this idea to the text (p. 2, l. 24-29/right): “Apparently a non-specific
interference effect is observed  …. and possibly causing the observed greater
cytotoxicity (compared to G2,3-KL and G2,3-RL)”
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
4.Why did the authors not compare the best dendrimer to L2000 in a dose-response to
really characterize the differences in potency.
We have now added data on optimisation the best L2000 formulation (Supplementary
Figure S3). We have chosen the best L2000 formulation to compare with our PD
formulation for the gene knockdown efficacy.
Similarly, why wasn't L2000 used a control for the cell uptake and biophysical studies.
We have now included cell uptake and biophysical data of L2000 in supplementary
Figures S3 and S4.
5.Introduction - what is an siRNA with 2'-overhangs?
Sorry – we meant 3’-overhangs (now also highlighted in the SI in ‘Experimental
procedures’, p. S13).
6.Introduction - the LNP platform being used for siRNA delivery in the clinic is the clear
front-runner
We have added two references to highlight how advanced these formulations are. (p.
4, l. 19-22/left: “While clinical use (as for the much more advanced lipid nanoparticles
[19]) remains so far just a long-term ambition, PDs join the arsenal of siRNA delivery
reagents as a new class”)
Section/Category:
Additional Information:
Question Response
Submitted solely to this journal? Yes
Has there been a previous version? No
Dedication
Animal/tissue experiments? No
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
COMMUNICATION          
Submitted_Manuscript 
 
 
 
Efficient Transfection of siRNA by Peptide Dendrimer-Lipid 
Conjugates  
Albert Kwok,[b]  Gabriela A. Eggimann,[a] Marc Heitz,[a] Jean-Louis Reymond,*[a] Florian Hollfelder*[b]  
and Tamis Darbre*[a] 
Abstract: Efficient small interfering RNA (siRNA) delivery into cells 
is the basis of target gene specific silencing and, ultimately, gene 
therapy. However, current transfection reagents are relatively 
inefficient and very few studies provide the sort of systematic 
understanding based on structure-activity relationships that would 
provide rationales for their improvement. This work establishes 
peptide dendrimers (administered with cationic lipids) as siRNA 
transfection reagents and records structure-activity relationships that 
highlight the importance of positive charge distributed in the two 
outer layers and a hydrophobic core as key features for efficient 
performance. These transfection reagents work as well as highly 
optimized commercial reagents, yet show less toxicity and fewer off-
target effects. More generally, the degrees of freedom in the 
synthetic procedure will allow the placing of decisive recognition 
features to enhance and fine-tune transfection and cell specificity.  
The therapeutic potential of gene silencing by RNA interference 
(RNAi) is based on downregulation of a target gene. This is 
achieved by the intracellular action of double-stranded short 
interfering RNA (siRNA; in this work a 21 base-paired RNA with 
3’-overhangs) that promotes the degradation of complementary 
mRNA via the RISC complex. In order to reach the place of 
action, siRNA needs to be delivered into the P-body in the cell. 
Delivery into the cytosol is crucially dependent on chemical 
transfection reagents that transport siRNA efficiently and safely 
to its intracellular target site.[1] The success of transfection is 
determined by the efficiency of transporting the negative cargo 
into the cell, avoiding RNA degradation and minimizing the 
toxicity of transfection complexes.  Despite enormous activity in 
the area, extracellular and intracellular barriers are still 
significant bottlenecks, render transfection inefficient and thus 
need to be overcome. A variety of transfection reagents, usually 
combining hydrophobic and cationic features, have been tested, 
[2] yet a systematic understanding of how to manipulate and 
control the efficiency and mode of cellular uptake, intracellular 
transport and endosomal release remains challenging.  
 Cationic lipids [2a, 3], polymers [4] dendrimers [5], dendrimer-like 
structures [5g, 6], peptides [7], nanocarriers [8], nanoparticles [9] 
nanocapsules [10] and supramolecular complexes [11] are 
examples of carrier vehicles that transport siRNA into cells. 
However, efficiency, toxicity and stability in serum need to be 
further improved. Furthermore, in many cases the molecular 
basis of the observed effects is hard to delineate. Structure-
activity relationships that would provide means to rationally 
manipulate the observed effects are rare, emerging sometimes 
from polydisperse systems [4c], but mainly from analysis of 
monodisperse reagents [2b, 11a, 12]. 
Peptide dendrimers (PDs)[13] are a new class of 
monodisperse transfection reagents, but have so far only been 
used for the transfection of plasmid DNA [12c]. They have been 
shown to be efficient DNA transfection reagents and obeyed 
systematic structure-activity relationships [12c]. A key determinant 
of efficiency was shown to be the location of cationic charges 
across three dendrimer generations, a feature that had not been 
accessible in other transfection reagents (see Figs. 1 and S1, SI 
for the structural formulae). Double stranded siRNA is more 
compact than DNA and acts in the cytosol rather than in the 
nucleus. Therefore efficient reagents for plasmid delivery are not 
necessarily active in siRNA transfection.[14] We now show that 
members of the same group of PDs originally shown to be active 
on DNA also transfect RNA. However, variation of the amino 
acid building blocks throughout the dendrimer suggests that 
transfection is governed by different rules for RNA vs DNA. 
Thus, a library of third generation PDs [12c] displaying lysine (K) 
or arginine (R) as cationic residues and leucine or alanine as a 
hydrophobic moieties and dimerized KL (=LysLeu) dendrimers 
(shown in Table 1; see the SI for detailed synthetic procedures 
and characterization of the PDs) was tested in a gene knock-out 
assay. Table 1 shows the 14 structures of the PDs tested, which 
are referred to in the text by abbreviations that highlight the 
pattern in the dendrimer generational layers (e.g. G2,3-KL has 
the motif KL in generation 2 and 3 and LL in generation 1; see 
Figure 1).   
    (a)    Dr. G. Eggimann, Dipl-Chem. M. Heitz, Prof. J. L. 
            Reymond, PD Dr. T. Darbre 
            Department of Chemistry and Biochemistry 
            University of Bern 
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            jean-louis.reymond@dcb.unibe.ch 
    (b)   Dr. A. Kwok, Prof. F. Hollfelder 
           Department of Biochemistry 
           University of Cambridge 
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The success of siRNA transfection was measured by 
experiments in which HeLa cells were treated with an siRNA 
designed to target the enzyme GAPDH (siGAPDH)[14] and a 
combination of the PDs (at an N/P ratio of 10) with cationic lipid/ 
neutral helper lipid DOTMA/DOPE (DOTMA: 1,2-dioleyloxy-3-
trimethylammonium propane chloride, DOPE: 1,2-dioleoyl-
glycero-3-phosphatidylethanolamine; administered in a w/w ratio 
of 2:1 to siRNA). The transfection efficiency was quantified by 
monitoring the decrease in GAPDH enzyme activity (evaluated 
with a fluorescence assay).[14] To rule out that gene silencing is 
due to a non-specific effect, a validated siRNA (siNC) was used 
as a control (see SI). All fourteen PDs showed (when 
administered in combination with DOTMA/DOPE) some degree 
of transfection. None of them showed activity in the absence of 
the cationic lipids (SI Figure S2). The best candidates, G2,3-KL 
and G2,3-RL exhibited 70% and 65% gene knock down, 
respectively. This represents significant gene silencing when 
compared to the DOTMA/DOPE-siRNA complex (p<0.05) and 
also to untreated cells (being comparable to the highly optimized 
commercial reagent L2000; Figure 2A). L2000, however, suffers 
from strong off-target effects: we observed 35% GAPDH 
knockdown even when using a non-specific siRNA (siNC, see SI 
Figure S3), where no knock-down of GAPDH should be 
observed. Apparently a non-specific interference effect is 
observed for L2000-siRNA, affecting the expression pattern of a 
number of genes[15] and possibly causing the observed greater  
cytotoxicity (compared to G2,3-KL and G2,3-RL). In particular for 
molecular therapy approaches the imprecision caused by such 
non-specific effects would be detrimental and the avoidance of 
off-target activity gives PDs an advantage. 
The physically associated dendriplexes were prepared by 
simply mixing dendrimer with DOTMA/DOPE and siRNA (see 
the SI for a typical experimental procedure). When the 
transfection efficiency of PDs with different cationic patterns in 
different generations was compared (KK vs KL vs RL, i.e. 
LysLys vs LysLeu vs ArgLeu), the dendrimers with KL (=LysLeu) 
or RL (=ArgLeu) were consistently more efficient than the ones 
with two lysines (e.g. G2,3-KK vs G2,3-KL or G2,3-RL; G1,2,3-
KK vs G1,2,3-KL or G1,2,3-RL, p<0.05). The dendrimer G1,2,3-
KK, a monodisperse polylysine dendrimer with a lysine diad 
within all the generations, performed worst in siRNA 
transfection, when compared to alternating charged and 
hydrophobic residues (G1,2,3-KL or G1,2,3-RL, p<0.05; see the 
SI p.2 for statistical analysis). Indeed, the KK series of PDs was 
less effective in gene silencing when compared to 
DOTMA/DOPE alone (Figure 2A). All PDs performed 
significantly better at silencing of the target gene than linear 
polylysine sequences (p<0.001): complexes of K24 and K32, 
respectively, siRNA and DOTMA/DOPE mediated no significant 
gene knock-down and caused higher cytotoxicity (Figures 2B). 
This observation suggests that the globular dendritic structure is 
beneficial, possibly by providing better encapsulation or 
protection to facilitate cellular siRNA uptake (Figures 3 and 4), 
when compared to the more rigid linear lysines, which are not as 
effective.[16] At the same time PD/lipid combinations showed low 
or barely measurable toxicity, as determined by crystal violet 
viability assays (Figure 2B). 
A clear trend was identified by comparison of dendrimers 
with the same amino acid composition, but different structural 
arrangements of these same amino acids in the dendrimer: the 
best transfection reagents have hydrophobic residues in the first 
generation and alternating hydrophobic/charged residues in the 
second and third generations, which induced significant gene 
silencing compared to all other PD complexes, DOTMA/DOPE, 
the respective siNC and untreated cell controls (p<0.05) (e.g. 
G2,3-KL or G2,3-RL). The correlation of transfection efficiency 
with the alternating pattern is independent of the type of charged 
residue (e.g. G2,3-KL or G2,3-RL). These rules differ from those 
derived for DNA transfection: spreading the charge throughout 
the dendrimer contributed to efficient transfection of DNA, while 
concentration of charges at the surface seemed to be more 
important for siRNA. Increasing the size of the dendrimers by 
dimerization tended to be detrimental to activity for siRNA (e.g. 
G2,3,-KL vs [G2,3,-KL]2), but was enhancing DNA 
transfection.[12c] The charge density (molecular weight to charge 
ratio) of PDs had been shown to be important in governing DNA 
delivery[12c] while there is no such correlation for siRNA. This 
difference suggests that the delivery of siRNA depends on 
physical dendrimer characteristics that remain to be specified. 
CD spectroscopy showed that the more active G2,3-KL, G2,3-
RL, G1,2,3-KL and G1,2,3-RL differ from the more hydrophobic 
G3-KL and G3-RL in their conformation in solution (Fig. 3A), 
while diffusion 1H NMR indicated that the less active G3-KL and 
G3-RL are less compact than the active dendrimers (Table 2).  
Dynamic light scattering measurements demonstrated that the 
KL, RL series form smaller siRNA complexes with increased 
charges and more compact complexes than DOTMA/DOPE 
alone (Fig. 3B).  These empirical correlations indicate structural 
effects, even though they may not necessarily be the direct 
cause of variations in gene silencing efficiency.  
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The properties of the dendriplex consisting of PD, lipid and 
RNA were analyzed in the following experiments that track the 
stages of the transfection process, namely assembly of the 
dendriplex and its stability, possible dissociation and cell 
penetration  
(i) Complex stability. Differences in binding and unloading 
properties of these new complexes were tested with PicoGreen-
labelled siRNA, which was mixed with combination of 
DOTMA/DOPE (2:1 to siRNA, w/w) and PDs at different N/P 
ratios (from 0.6 to 20). Binding of siRNA to PD results in 
quenching of the fluorescence of PicoGreen: thus a low signal 
indicates complex formation. Figures 4A and B show which 
dendrimers formed stable complexes with siRNA (starting from 
N/P ratios of 5 and 10). Apparently the charge distribution on the 
dendritic skeleton influences the binding ability. The three PDs 
containing a KK (LysLys) motif bound the siRNA similarly well. 
PDs with LysX (X = Leu, Ala, His) units showed a wider range of 
siRNA binding: G3-KL gave the largest decrease in PicoGreen 
signal, whereas G2,3-KL, G1,2,3-KL, G1,2,3-KA and G1,2,3-KH 
showed lower siRNA binding. The trend was similar for the 
corresponding homodimers of the KL (LysLeu) series. G2,3-RL 
and G3-RL, bind to siRNA similarly, suggesting the RL (ArgLeu) 
dendrimers formed stable complexes with the siRNA mixture 
with a less pronounced dependence on the total charge or 
number of charged residues with the generations, compared to 
the KL (LysLeu) and KK (LysLys) species.   
(ii) Dissociation. Further insight into dissociation of 
siRNA/PD/lipid complexes was obtained by a competition assay 
with the negatively charged heparin as a challenger. The siRNA 
dendriplexes (N/P ratio of 10:1) were treated with heparin at 
different concentrations (Figs. 4C and 4D), so that a threshold 
concentration could be determined at which heparin out-
competed the RNA. The effect of charge distribution on the 
binding strength was again evident (in Figure 2E and F): the 
most effective siGAPDH silencing complexes G2,3-KL and 
G2,3-RL were neither the strongest or weakest siRNA binders 
(60% and 35% of siRNA release at 1.5 U/mL of heparin, 
respectively). It may be possible that dendrimers that bind 
siRNA too strongly hinder its release in the cells, while weaker 
siRNA binding results in untimely dissociation of the constructs, 
lowering the window for complex uptake and activity. 
(iii) Uptake. The uptake of the short interfering RNA into HeLa 
cells was evaluated by flow cytometry. Cy3-labelled RNA, with 
the PD (N/P ratio of 10) and DOTMA/DOPE (2:1 to siRNA, w/w) 
and siGAPDH were added to cells. After transfection (4 hours), 
the cells were washed with heparin to remove any surface-
bound siRNA, prior to trypsinization and analysis by flow 
cytometry (Figure 5).  
For the KL series, G1,2,3-KL clearly showed lower cell uptake, 
whereas G3-KL and G2,3-KL gave similar RFU signals. The 
same trend was observed for their corresponding homodimers 
(Fig. S4 SI). The RL PDs also showed a similar pattern for the 
three different dendrimer scaffolds, in which the overall 
fluorescence signal for the individual complexes was stronger 
compared to the analogous KL compounds, suggesting better 
uptake into HeLa cells. Overall, the observation that G1,2,3-KL 
and G1,2,3-RL did not show strong uptake can be explained by 
the weaker siRNA binding.  The observation that G3-KL and G3-
RL did not show better transfection can be rationalized by their 
weak siRNA dissociation, i.e. an inability to set their cargo free. 
The analogues, in which leucine was replaced by alanine 
(G1,2,3-KA) or histidine (G1,2,3-KH), gave similar Cy3 signals, 
indicating that the nature of the hydrophobic residue does not 
influence the transfection ability of the complexes. The uptake of 
the lipid-dendrimer-siRNA complexes evidently correlates with 
the transfection efficiency (see Figure S4, SI, for the remaining 
dendrimers and controls). 
Taken together the results indicate that the interplay of charged 
and hydrophobic residues is necessary for efficient transfection: 
the PD with lysine residues in the branches only (and 
consequently the highest total charge) is the least effective 
reagent. The same observation was made with the linear 
sequences K24 and K32, both not performing well in transfection 
assay. Placing positive charges only on the peripheral layer is 
also not sufficient for efficiency. There is a subtle balance 
between the number of positive charges, the nature of the 
cationic residue and the distribution of charges through the 
dendritic structure that jointly determine the efficiency of a 
transfection reagent (when administered with DOTMA/DOPE). 
The right combination is achieved in the dendrimers G2,3-KL 
and G2,3-RL, which also appear to provide a less compact 
conformation in solution that favors complexation, a unique 
property of the dendritic nature of this new transfection reagents. 
Overall the activity of dendrimers with lysine and arginine are 
similar: G2,3-KL and G2,3-RL are the most active PDs (70% and 
65 % GAPDH activity silencing respectively, Table 1). Changing 
the hydrophobic residue from leucine to alanine or histidine in 
the PDs did not influence the GAPDH activity substantially, 
consistent with the idea that it is the pattern of hydrophobic and 
cationic residues rather than a specific feature of the dendritic 
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structure that plays an important role in the transfection ability of 
dendrimers.    
PDs with a branched and flexible architecture are well suited to 
form stable complexes with short and rigid siRNA molecules. 
The requirement for flexibility has already been highlighted for 
the related polyamidoamine dendrimers (PAMAM), which are 
too rigid for efficient binding and delivery. Degraded PAMAM 
dendrimers were shown to be more suitable transfection 
agents[17] and our work provides a possible explanation, by 
showing that structures with greater flexibility can be more 
effective.  However, in other systems (such as triazine 
dendrimers) rigid structures were more effective. This 
discrepancy could be due to the very different chemical 
composition and the resulting intrinsic properties of the scaffold 
that influences siRNA binding.[5c, 18] 
These guidelines could be drawn up only because - in contrast 
to the overwhelming majority of transfection reagents described 
previously – systematic variation of PD structure was possible 
and gave rise to structure-function relationships. While clinical 
use (as for the much more advanced lipid nanoparticles [19]) 
remains so far just a long-term ambition, PDs join the arsenal of 
siRNA delivery reagents as a new class in which exploration of 
chemical diversity can help rationalize efficiency gains to provide 
a framework for the design of effective and safe transfection 
reagents in the future.  Well-defined PD structures are easily 
synthesized by solid phase peptide synthesis (SPPS) from 
natural or unnatural amino acids,[20] which will make this new 
class of RNA transfection reagents readily accessible.  
Experimental Section 
Synthesis. The peptide dendrimers were prepared by solid phase peptide 
synthesis and isolated by HPLC to give pure compounds showing the 
expected mass by ESI/MS (see Supporting Information, SI). 
siRNA binding and dissociation assays. To assess the binding properties 
of the siRNA to the dendrimers and DOTMA/DOPE, PicoGreen labeled 
siRNA was incubated with the reagents for 30 minutes at room 
temperature. The PicoGreen signals were then detected with a 
fluorescent plate reader, FLUOstar Optima. To assess the dissociation 
properties of the siRNA from the dendrimers and DOTMA/DOPE, 
complexes were formed as described above and were then subjected to 
a challenge with heparin for 30 minutes at room temperature. The 
PicoGreen signal was recorded using FLUOstar Optima. The PicoGreen 
signals from the complexes were normalized against a ‘siRNA only’ 
control to yield the percentage of the PicoGreen signal detected. L2000 
was used as a control.   
siRNA transfection and cell viability measurement. HeLa cells were 
transfected with siRNA transfection complexes formed from dendrimers, 
DOTMA/DOPE and siRNA for 4 hours. The transfection complexes were 
replaced by full growth medium following the transfection for 48 hours, 
and the GAPDH activity was then assayed. To measure cell toxicity that 
may cause by transfection, the cells were transfected as described, 
washed and stained with the nuclear dye Crystal Violet. The remaining 
dye was then dissolved in methanol and quantified by its absorbance at 
550 nm. Validated non-targeting siRNA and L2000 were used as controls. 
Experiments in the absence of DOTMA/DOPE showed inefficient 
transfection (as in our previous work with DNA transfection[12c]) and non-
specific knockdown effects.  
Flow cytometry.  To analyze siRNA complex uptake in the HeLa cells, 
Cy3-labelled siRNA were mixed with dendrimers and DOTMA/DOPE, 
and the complexes were used to transfect the cells for 4 hours. The cells 
were then washed with heparin and PBS before analyzed by a flow 
cytometer CyAn ADP. 
Statistical analysis. The data presented in this study was analyzed using 
a two-tailed, unpaired Student t-test and one-way or two way ANOVA 
followed by a post-hoc test when appropriate. 
The Supporting Information contains details of peptide dendrimer 
synthesis and characterization (1H NMR, DOSY-NMR, RP-HPLC 
chromatograms, hydrodynamic radii, CD spectra, mass spectra, 
transfection protocols, DNA binding assays, complex dissociation assay, 
cell viability assay, flow cytometry and statistical analysis.  
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Figure 1. Structure of peptide dendrimer G2,3-KL as an 
example of the collection tested in this work. The shorthand 
G2,3-KL represents that this PD has an LL diad in the first 
generation (G1) and a KL diad in the second (G2) and third (G3) 
generations. The branching lysines are shown in italics. The 
cysteine residue is the C-terminus (amidated) and the eight 
lysines in the G3 are the N-termini with free amino groups. Full 
formulae are shown in Table 1 and complete chemical structures 
of all compounds tested are shown in the SI. 
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Figure 2. [A] Transfection by physically associated lipid-dendrimer-siRNA complexes. [B] Cell viability following transfection by lipid-
dendrimer-siRNA complexes. HeLa cells were transfected with siGAPDH (siRNA targeting GAPDH) and siNC (non-active siRNA 
control) using dendrimers (N/P ratio = 10:1) and DOTMA/DOPE (w/w ratio = 2:1).  Error bars refer to the mean ± SD carried out in 
sextuplicate. See the SI for detailed experimental protocols and for statistical analysis of the significance of the differences in gene 
silencing observed. 
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A 
 
B 
 
Figure 3. Biophysical characterisation of PDs. (A) CD spectra of 0.1 mg/mL peptide dendrimers in phosphate buffer (pH 7.4) at room 
temperature. (B) Hydrodynamic diameters of the lipid-dendrimer-siRNA complexes. siRNA (10 µg) was added to the dendrimers at 
an N/P ratio of 10:1 in the supplement with DOTMA/DOPE (w/w=2:1) at room temperature. The DOTMA/DOPE and siRNA 
complexes were used as a control. Following a 30 minute incubation, the complexes were transferred to a low-volume transparent 
cuvette for the hydrodynamic diameters measurement. The hydrodynamic diameter was recorded and analysed by Dynamic Light 
Scattering. n=3-7 for each formulation and SD is shown. All the data shown have a PDI lower than 0.5.  
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Figure 4. [A] and [B] Binding data of lipid-dendrimer-siRNA complexes. PicoGreen-labelled siGAPDH was used to form complexes 
with dendrimers at different N/P ratios, in the presence of DOTMA/DOPE (2:1 to siRNA w/w). The PicoGreen signal detected from 
the complexes was normalized by the siRNA alone control to yield the percentage of PicoGreen signal detected. [C] and [D] siRNA 
unloading data of lipid-dendrimer-siRNA complexes. Complexes were formed as described in [A], then, the complexes were 
challenged with heparin. Error bars refer to the mean ± SD for experiments carried out in triplicates.  
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Figure 5. Cellular uptake of lipid-dendrimer-siRNA complexes. HeLa cells were transfected with complexes of Cy3-labelled siGAPDH 
(50 pmol, 25 µL) with dendrimers (N/P = 10) and DOTMA/DOPE (2:1 to siRNA, w/w) for 4 hours. Transfected cells were washed (3 
times) with heparin solution (2 mg/mL) to remove surface-bound siRNA. The cells were then treated with trypsin and the 
internalization of the siRNA complexes was measured by flow cytometry (RFU: relative fluorescence units). See Fig. S4, SI for the 
controls. 
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Table 1. Peptide dendrimers (PDs) studied in this work. PDs are identified by the generation modified (G) and the substitution pattern in this shell (e.g. G3-KK has 
the motif KK in the third shell and the motif LL in the first and second shell; G1,2,3-KK  has a KK motif in all three shells. See the SI for full chemical structures.  
 
Transfectant 
Sequencea Total 
charge 
(+)b 
Side chains GAPDH 
Activity 
[%]d Charged 
(+)c   
Hydro- 
phobic 
G3-KK (KK)8(KLL)4(KLL)2KGSC 24 16 - 54 ± 17 
G2,3-KK (KK)8(KKK)4(KLL)2KGSC 32 24 - 61 ±18 
G1,2,3-KK (KK)8(KKK)4(KKK)2KGSC 36 28 - 80 ± 16 
G3-KL (KL)8(KLL)4(KLL)2KGSC 16 8 20 60 ± 12 
G2,3-KL (KL)8(KKL)4(KLL)2KGSC 20 12 16 30 ± 5 
G1,2,3-KL (KL)8(KKL)4(KKL)2KGSC 22 14 14 56 ± 16 
G3-RL (RL)8(KLL)4(KLL)2KGSC 16 8 20 84 ± 10 
G2,3-RL (RL)8(KRL)4(KLL)2KGSC 20 12 16 35 ± 3 
G1,2,3-RL (RL)8(KRL)4(KRL)2KGSC 22 14 14 36 ± 5 
G1,2,3-KA (KA)8(KKA)4(KKA)2KGSC 22 14 14 49 ± 18 
G1,2,3-KH (KH)8(KKH)4(KKH)2KGSC >22c 14 >14c 66 ± 21 
[G3-KL]2 [(KL)8(KLL)4(KLL)2KGSC]2 32 16 40 55 ± 10 
[G2,3-KL]2 [(KL)8(KKL)4(KLL)2KGSC]2 40 24 32 58 ± 10 
[G1,2,3-KL]2 [(KL)8(KKL)4(KKL)2KGSC]2 44 28 28 55 ± 20 
Linear K24  K24 24 - - n.d 
Linear K32  K32 32 - - n.d 
DOTMA/DOPE n.a n.a - - 68 ± 9 
L2000 n.a n.a - - 22 ± 3 e 
 
a) One letter codes for amino acids. Branching lysines in italics. All peptides are carboxamide (CONH2) at the C-terminus. b) Number of cationic amino acid 
residues (Lys or Arg) and free N-termini. c) R or K. d) His residues are partially protonated at pH 7. d GAPDH activity (%) is defined by the remaining GAPDH 
activity following transfection normalised against the GAPDH activity of untreated cells (set as 100%). e) siRNA transfection with L2000 leads to the knock-down of 
more than one gene. This non-specific gene knockdown is significant and amounts to 35%. By contrast, all PDs only affect the targeted GAPDH.  
The mean ± SD is for experiments carried out in sextuplicate; n.d: not detectable above the siNC or untreated cells (< exp. error); n.a: not applicable.  
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
COMMUNICATION          
Submitted_Manuscript 
 
 
Table 2. Hydrodynamic radii of the peptide dendrimers. 
Compound Solvent pH radius[a] 
G3-KL D2O ≈7.4 3.71±0.18 
G2,3-KL D2O ≈7.4 2.22±0.02 
G1,2,3-KL D2O ≈7.4 2.3±0.04 
G3-RL D2O ≈7.4 4.15±0.23 
G2,3-RL 
D2O ≈7.4 
2.27±0.03 
G1,2,3-RL D2O ≈7.4 2.52±0.04 
  
[a] The hydrodynamic radii Rh were calculated from diffusion coefficients D, which 
are the median values from an intensity fit analysis of different 1H signals, were 
calculated from the Stokes-Einstein equation Rh = k*T/6D, with Boltzmann 
constant k = 1.380*10-23 J*K-1, temperature T = 303 K and viscosity 
h = 1.089 mPa*s for D2O.  
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